ScholarIQanswers from OpenAlex & ORCID
Shun Lü
ResearcherPublications, citations & collaboration network
Shun Lü is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Shun Lü have?
ScholarIQindexed works
Shun Lü has 911 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Shun Lü have?
ScholarIQcitation count
Shun Lü has 38,482 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Shun Lü?
ScholarIQh-index
Shun Lü has an h-index of 78 in OpenAlex.
What is the i10-index of Shun Lü?
ScholarIQi10-index
Shun Lü has an i10-index of 311 in OpenAlex.
What is the ORCID of Shun Lü?
ScholarIQorcid
The ORCID for Shun Lü is on the source record.
What is the OpenAlex record for Shun Lü?
ScholarIQopenalex
The OpenAlex for Shun Lü is on the source record.
What are the most-cited papers on Shun Lü?
ScholarIQmost cited works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi‐Long Wu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Chong‐Rui Xu, Dan Massey, Miyoung Kim, Yang Shi, Sarayut Lucien Geater
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
Yi‐Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Terufumi Kato, Huu-Vinh Vu, Shun Lü, Kye Young Lee, Charuwan Akewanlop, Chong‐Jen Yu, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Lingmin Zeng, Rachel Hodge, Ajlan Atasoy, Yuri Rukazenkov, Roy S. Herbst
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler, Martin Sebastian, Sanjay Popat, Nobuyuki Yamamoto, Caicun Zhou, Cheng-Ping Hu, Kenneth J. O’Byrne, Jifeng Feng, Shun Lü, Yunchao Huang, Sarayut Lucien Geater, Kye Young Lee, Chun-Ming Tsai, В. А. Горбунова, Vera Hirsh, Jaafar Bennouna, С. В. Орлов, Tony Mok, Michael Boyer, Wu‐Chou Su, Ki Hyeong Lee, Terufumi Kato, Dan Massey, Mehdi Shahidi, Victoria Zazulina, Lecia V. Sequist
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Yi‐Long Wu, Caicun Zhou, Chong Kin Liam, Gang Wu, Xuan Liu, Zhaoyang Zhong, Shun Lü, Ying Cheng, Baohui Han, Lin Chen, Cheng Huang, Shanshan Qin, Yixiang Zhu, Hui Pan, Houjie Liang, Elizabeth Li, Guangliang Jiang, Soon Hin How, Mitchel Fernando, Y. Zhang, Fan Xia, Yanchen Zuo